Senseonics Holdings (SENS) Fair Value & Analysis
Healthcare · US · Market cap $327M
Senseonics Holdings
SENS · US
Fair value as of: Jun 24, 2026
From 4 valuation models · updated 5 days ago
Share price −12.5% over the past month.
Price vs Fair Value (12 months)
12‑month range $5.08 – $11.88 · fair‑value band $3.95 – $6.58 · the $6.04 price screens above the $5.26 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Senseonics Holdings (SENS) currently trades at $6.04, while our model-based Fair Value estimate is $5.26 — implying the stock looks roughly 12.9% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at $40.7M. Revenue grew 87.2% year over year. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. Its products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Senseonics Holdings reported revenue of $35.3M in FY2025 versus $13.7M in FY2021, a compound +26.7%/yr. Reported net income was −$69.1M in FY2025.
Open the full interactive analysis →
Recent news
- Senseonics Expands Eversense 365 Ecosystem With Welldoc Partnership
- European Insider Growth Leaders For June 2026
- Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Syste
- 3 Asian Growth Companies With High Insider Ownership Growing Earnings At 16%
External third-party headlines (Yahoo Finance, Reuters and others) — not an editorial selection, not financial advice.
Similar stocks
6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | 1,600 MXN | 1,228 MXN | -23% |
| Stryker Corporation S1YK34 | R$79.21 | R$43.74 | -45% |
| Medtronic plc MDT | $80.25 | $74.40 | -7% |
| Boston Scientific Corporation B1SX34 | R$248.75 | R$221.81 | -11% |
| Edwards Lifesciences Corporation EW | $85.88 | $41.02 | -52% |
| Siemens Healthineers AG SEMHF | $40.29 | $47.96 | +19% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Senseonics Holdings (SENS) undervalued?
What is the fair value of SENS?
What is the quality score of SENS?
What is the revenue of Senseonics Holdings (SENS)?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.